Elan Corporation PLC Reports Higher Q1 Loss, Progress for MS Drug

AP -- Irish biopharmaceutical company Elan Corp. PLC reported a widening net loss in its first-quarter results Wednesday due to restructuring costs, but said sales improved for its key multiple sclerosis drug Tysabri.